The Occasional Papers series is intended to provide a forum for examining a wide range of topics of interest to the hemophilia community. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph.
Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff. The Development of the Programme
The goals of treatment of haemophilia can be summarised succinctly as follows: "to minimise disability and prolong life, to facilitate general social and physical well-being and to help each patient achieve full potential, whilst causing no harm" [1] . Whilst much has already been achieved in wealthier countries, the outlook for people with haemophilia in poorer countries remains bleak. The WFH estimates on the basis of recent global surveys that approximately 70% of people with haemophilia around the world remain undiagnosed and therefore receive no treatment. The WFH Decade Plan, published in 1992, recognised the paramount importance of fostering the development of haemophilia care in developing countries [2] . This principal goal of this ambitious strategy is to encourage and foster the highest possible levels of diagnosis and comprehensive care for people with haemophilia and related disorders throughout the world, and to establish programmes which address the local issues which restrict access to comprehensive care for people with haemophilia in the developing world. It was appreciated that one way of achieving these goals was to encourage the creation of strong ties between professionals working in haemophilia centres in developed and developing countries. The concept of a twinning programme was thus proposed by Prof. Guglielmo Mariani. The scheme was subsequently approved by the WFH Council in October 1993 and Prof. Mariani was appointed as the first chairman of the twinning committee.
In the early years of the programme, those centres already designated by the WFH as International Haemophilia Training Centres (IHTC) were primarily involved and forged the first formal partnerships [3] . These were often based on pre-existing informal partnerships which were usually cemented by historical, linguistic, cultural and/or political links. Since then, many other centres have become involved in the programme as it has expanded and evolved and designation as an IHTC is certainly no longer a prerequisite for involvement in the scheme.
Aims of the Twinning Programme
The WFH Haemophilia Treatment Centre Twinning Programme promotes the development of a collaborative network of haemophilia centres around the world. Established centres with the necessary knowledge, experience and resources can help emerging centres improve treatment and directly improve the level of care to patients by sharing and transferring these skills. WFH has developed a step-by-step model for development of haemophilia care, and one of the main aims of the twinning programme is to foster the model of comprehensive care for people with haemophilia, involving teams of professionals from several disciplines.
Examples of some of the principal types of twinning activities include:
1. Providing medical advice on the management of clinical problems and complex cases. Good communication links, using e-mail or fax, need to be established and maintained.
2. Training to pass on knowledge and skills. This can be achieved by exchange visits, so both partners become familiar with each other's situation, or on-site when staff from one site train others at the site of their partner. For example, good laboratory training helps to ensure correct diagnosis as well as appropriate management of haemophilia and related conditions.
3. Donation of laboratory equipment and reagents, and/or coagulation factor concentrates. If donating equipment, some consideration needs to be given to issues such as availability and cost of reagents and spare parts. Participation in external quality assurance schemes for the appropriate laboratory tests is also to be encouraged. Some financial support from WFH is available for twinned partners although it must be appreciated that this is limited and twins from more developed countries usually secure additional funding from other sources to support their activities. The importance attached to the twinning programme is reflected by the growing budget allocated to the scheme by the WFH Executive Committee, which is now approximately US$ 120,000 per year (5% of the total WFH budget). The programme is supported by generous sponsorship from Wyeth in the form of an unrestricted financial grant amounting to more than US$ 700,000 over a three-year period. This grant has allowed the programme to expand, both in terms of the numbers of twinned partners abut also as regards the financial allocation available to each pair. Funding is offered for an initial assessment visit when a link is planned. Regular annual grants of US$ 1500 are awarded and there is also the possibility of applying for additional funding to support specific projects. Such additional grants typically amount to US$ 2000-8000). WFH is also able to offer free subscriptions to the journal "Haemophilia" to twinning partners which would otherwise not be able to afford this journal. It is important to bear in mind that the World Federation of Haemophilia, like many other international charitable or not-for-profit organisations, does not provide any form of insurance or other indemnity for volunteer workers against malpractice or accident in view of the prohibitive cost this would entail. All health care professionals working away from their own hospitals or countries should therefore limit their role to a purely advisory one, unless their personal medical malpractice or other insurance specifically includes cover for such work. The same caveat applies to donations of any coagulation factor concentrates.
Approved Partnerships:
Currently, a total of 22 treatment centres around the world are linked through the twinning programme. 7 twinning partnerships have recently closed but a further 10 new applications are currently are under active consideration.
Lists of current and recently-closed twinning partners are presented in 
Joining the Twinning Programme
The WFH twinning initiative is an active and growing programme. Expressions of interest are positively welcomed from centres hitherto not involved in this scheme but which have with the necessary experience, skills and resources. Application forms and a copy of the illustrated WFH brochure "Improving care beyond our borders: a twinning guide for hemophilia treatment centres" should be obtained from Karine Frisou, Twinning Coordinator at the WFH office in Montreal. Applications are considered by the WFH twinning committee and evidence will be sought of genuine commitment to the programme, not just on the part of senior medical personnel but also from the multidisciplinary staff of the treatment centre. Clear support from the hospital administration is also desirable. The centre should also have the spare capacity to take on this additional work, including allowing staff time off from usual duties to travel abroad and also to receive visitors from abroad for periods of training. With regard to developed countries, the programme is primarily suitable for larger comprehensive care centres, which offer broad exposure to most aspects of haemophilia care.
If you do not have a potential twinning partner in mind, the WFH staff can help you to identify a suitable match for your centre. Factors such as existing cultural links with your centre or country will be taken into consideration, as well as language skills of your staff. Existing links between the national member organisations (NMO's) may also be deemed relevant. For example, the UK Haemophilia Society is currently twinned with the Russian NMO, and it was therefore thought appropriate to twin the Children's Hospital in Moscow with Alder Hey Children's Hospital in Liverpool (UK). Once a potential twinning partner has been identified, funding for an assessment visit is provided. It is vital for key staff in your treatment centre to have a good understanding of your potential twin, and understand the issues relevant and important to them as well as to assess level of development and treatment available. The WFH will usually be able to supply you with data from the annual surveys, including information on demography, number of diagnosed patients and product/treatment availability. It is equally important to understand and value the culture and history of your potential twin. Such a visit also enables you to set realistic objectives and goals for the partnership over the relatively limited three-year period available. Assessment visit guidelines are available from the WFH and can help you gather useful information from your visit. During the visit you could prepare a general outline of a project or even a detailed action plan with your twinning partner. The action plan submitted with a proposal for twinning will require a clear statement of goals and objectives, with details of the key personnel involved and a proposed budget. The action plan should also outline plans to monitor progress and outcomes.
